Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Current Pharmaceutical Biotechnology|March 9, 2002
Phage display as a tool for protease ligand discoveryAndrew E NixonCurrent Opinion in Drug Discovery & Development|March 29, 2006
Engineered protein inhibitors of proteasesAndrew E Nixon, Clive R WoodMabs|November 23, 2013
Drugs derived from phage display: from candidate identification to clinical practiceAndrew E Nixon, Daniel J Sexton, Robert C LadnerJournal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 26, 2017
Choices of capture chromatography technology in antibody manufacturing processesMichael DiLeo, Arthur Ley, Andrew E Nixon, et al.Antibodies (Basel, Switzerland)|November 21, 2020
Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid TumorsVladimir Voynov, Paul J Adam, Andrew E Nixon, et al.Analytical Biochemistry|January 30, 2013
A homogeneous fluorescence anisotropy assay for measuring transglutaminase 2 activityJon A Kenniston, Gregory P Conley, Daniel J Sexton, et al.Frontiers in Molecular Biosciences|August 23, 2023
How can we discover developable antibody-based biotherapeutics?Joschka Bauer, Nandhini Rajagopal, Priyanka Gupta, et al.Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor BlockadeKazuyo Kaneko, Richard O Williams, Daniel T Dransfield, et al.Proceedings of the National Academy of Sciences of the United States of America|September 10, 2021
Intrinsic physicochemical profile of marketed antibody-based biotherapeuticsLucky Ahmed, Priyanka Gupta, Kyle P Martin, et al.Journal of Chromatography. A|October 13, 2009
The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification processJie Chen, Jen Tetrault, Yanyu Zhang, et al.Pageof 3